Evolution of fibrotic interstitial lung diseases (ILD) after COVID-19
M. Ramos Martins (Porto, Portugal), M. Serino (Porto, Portugal), B. Martins (Porto, Portugal), I. Carvalho (Porto, Portugal), C. Valente (Porto, Portugal), M. Barbosa (Porto, Portugal), C. Cascais-Costa (Porto, Portugal), M. Alves (Porto, Portugal), A. Terras-Alexandre (Porto, Portugal), N. Melo (Porto, Portugal), P. Caetano-Mota (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Morais (Porto, Portugal)
Source: International Congress 2022 – Clinical course and management of interstitial lung diseases
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Ramos Martins (Porto, Portugal), M. Serino (Porto, Portugal), B. Martins (Porto, Portugal), I. Carvalho (Porto, Portugal), C. Valente (Porto, Portugal), M. Barbosa (Porto, Portugal), C. Cascais-Costa (Porto, Portugal), M. Alves (Porto, Portugal), A. Terras-Alexandre (Porto, Portugal), N. Melo (Porto, Portugal), P. Caetano-Mota (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Morais (Porto, Portugal). Evolution of fibrotic interstitial lung diseases (ILD) after COVID-19. 1969
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|